ClinicalTrials.gg
CompletedNCT01147900Updated Aug 20, 2018Results posted

Evaluation of Boostrix™10 Years After Previous Booster Vaccination

A Phase 4 interventional study of Boostrix™ and Boostrix™-US formulation in Acellular Pertussis, Tetanus and Diphtheria, sponsored by GlaxoSmithKline. Completed at 3 sites in Belgium. Open to participants aged 18 Years to 28 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-20.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Non-randomized
Ages
18 Years to 28 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing boostrix in Tetanus — 2 open to participants now, 2 under way, none of them phase 3. Boostrix · Tetanus.

Enrollment
18th of 22
180 · median 554
Started
2010
the only one that year
Phase 4
8 of 22
none open now
Registered
11th of 22
by date
Lead sponsor
18 of 22
GlaxoSmithKline

Among the 22 studies testing boostrix in Tetanus, this one is the 18th largest by enrollment, is the only one that started in 2010, is one of 8 in phase 4, and was the 11th registered.

Tetanus

318 studies on the registry are indexed under Tetanus; 29 are open to participants now.

Browse Tetanus studies →

Open to participants now

2 of the 22 studies testing boostrix in Tetanus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About boostrix

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 16 Tetanus studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 28 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing boostrix in Tetanus, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the immunogenicity, safety and reactogenicity of a dTpa (Boostrix™ vaccine) booster dose given 10 years after the previous vaccination with dTpa in GSK 263855/029 study. Only subjects who were part of the primary study will be invited to participate in this study.This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate study (see reference).

Read the detailed description

All subjects will receive a booster dose of the vaccine that they received in their primary study. Subjects who received the investigational vaccine formulation, will receive Boostrix™ in the present study.

03

Conditions studied

  • Acellular Pertussis
  • Tetanus
  • Diphtheria

Browse trials for

Keywords

  • Immune persistence
  • Boostrix
  • dTpa booster study
04

Who can participate

Ages eligible
18 Years to 28 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol.
  • Male or female subjects who have received Boostrix™, Boostrix™-US formulation or the vaccine formulation in the study 263855/029.
  • Written obtained from the subject. Additional criteria to be checked before the booster vaccination.
  • Healthy subjects as established by medical history and clinical examination.
  • Female subjects of non- may receive the booster vaccine.
  • Female subjects of childbearing potential may receive the booster vaccine, if the subject:

    • practices/has practiced adequate for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • agrees to continue adequate contraception during the entire booster epoch.

Exclusion Criteria:

Exclusion criteria to be checked at study entry:

  • Previous booster vaccination against diphtheria, tetanus, or pertussis since the dose received in the study 263855/029.
  • History of diphtheria, tetanus, or laboratory confirmed pertussis disease.
  • Any confirmed or suspected or immunodeficiency condition, based on medical history and physical examination.
  • History of any reaction or likely to be exacerbated by any component of the vaccine.
  • Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus.
  • Occurrence of any of the following adverse event after a previous administration of a DTP vaccine :

    • hypersensitivity reaction to any component of the vaccine,
    • encephalopathy of unknown aetiology occurring within seven days following previous vaccination with pertussis-containing vaccine,
    • fever >= 40 °C (axillary temperature) within 48 hours of vaccination not due to another identifiable cause,
    • collapse or shock-like state within 48 hours of vaccination,
    • convulsions with or without fever, occurring within three days of vaccination.
  • Acute or chronic, pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.

Additional exclusion criteria to be checked for subjects before the booster vaccination administration:

  • Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the booster dose of study vaccine, or planned use during the study period.
  • Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the booster dose.
  • Administration of a vaccine not foreseen by the study protocol within 30 days prior to booster vaccination, or planned administration during the active study period.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the booster dose or planned administration during the study period.
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥ 37.5°C on oral, axillary or tympanic setting.
    • Subjects with a minor illness without fever may be enrolled at the discretion of the investigator.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Boostrix-REF Group

    Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, reference formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.

    Biological: Boostrix™

  • Experimental
    Boostrix-US Group

    Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, United States(US)-marketed formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, US-marketed formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.

    Biological: Boostrix™-US formulation

  • Experimental
    Boostrix-INV Group

    Subjects in this group were healthy adult subjects aged 18 to 28 years at the time of enrolment and with previous completed primary and booster vaccination with a diphtheria-tetanus-whole cell pertussis vaccine completed by one additional booster dose of Boostrix™ vaccine, investigational formulation, at Day 0 in GSK 263855/029 study. These subjects received, as part of this NCT01147900 study, one further booster dose of Boostrix™ vaccine, reference formulation, at Year 10, 10 years after booster vaccination in the GSK 263855/029 study. The Boostrix™ vaccine was administered intramuscularly in the deltoid muscle of the non-dominant arm.

    Biological: Boostrix™

Interventions

  • BiologicalBoostrix™

    Intramuscular, single dose

  • BiologicalBoostrix™-US formulation

    Intramuscular, single dose

06

What researchers measure

Primary outcomes

  1. Number of Seroprotected Subjects Against Diphtheria and Tetanus

    A subject seroprotected against diphtheria/tetanus was defined as a vaccinated subject who had an anti-diphtheria (anti-D)/anti-tetanus (anti-T) antibody concentration greater than or above (≥) 0.1 international units per milliliter (IU/mL).

    Time frame: At Year 8.5

  2. Concentrations for Anti-D and Anti-T Antibodies.

    Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL for all antibodies assessed.

    Time frame: At Year 8.5

  3. Number of Seroprotected Subjects Against Diphtheria and Tetanus.

    A subject seroprotected against diphtheria/tetanus was defined as a vaccinated subject who had an anti-D/anti-T antibody concentration greater than or above (≥) 0.1 international units per milliliter (IU/mL).

    Time frame: At Year 10

  4. Concentrations for Anti-D and Anti-T Antibodies.

    Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL.

    Time frame: At Year 10

  5. Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Haemagglutinin (Anti-FHA) Antibodies.

    A seropositive subject for anti-PT/anti-PRN/anti-FHA antibodies was defined as a vaccinated subject who had anti-PT/anti-PRN/anti-FHA antibody concentrations greater than or equal to (≥) 5 Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

    Time frame: At Year 8.5

  6. Concentrations for Anti-PT, Anti-PRN and Anti-FHA Antibodies.

    Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL for all antibodies assessed.

    Time frame: At Year 8.5

  7. Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN Antibodies.

    A seropositive subject for anti-PT/anti-FHA/anti-PRN antibodies was defined as a vaccinated subject who had anti-PT/anti-FHA/anti-PRN antibody concentrations greater than or equal to (≥) 5 Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

    Time frame: At Year 10

  8. Concentrations for Anti-PT, Anti-FHA and Anti-PRN Antibodies.

    Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL.

    Time frame: At Year 10

  9. Number of Seroprotected Subjects Against Diphtheria and Tetanus

    A subject seroprotected against diphtheria/tetanus was defined as a vaccinated subject who had an anti-D/anti-T antibody concentration greater than or above (≥) 0.1 international units per milliliter (IU/mL).

    Time frame: At Year 10 pre booster vaccination (PRE) and at 1 month post Year 10 booster vaccination (POST)

  10. Concentrations for Anti-D and Anti-T Antibodies.

    Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL for all antibodies assessed.

    Time frame: At Year 10 pre booster vaccination (PRE) and at 1 month post Year 10 booster vaccination (POST)

  11. Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN Antibodies.

    A seropositive subject for anti-PT/anti-PRN/anti-FHA antibodies was defined as a vaccinated subject who had anti-PT/anti-PRN/anti-FHA antibody concentrations greater than or equal to (≥) 5 ELISA units per milliliter (EL.U/mL).

    Time frame: At Year 10 pre booster vaccination (PRE) and at 1 month post Year 10 booster vaccination (POST)

  12. Concentrations for Anti-PT, Anti-FHA and Anti-PRN Antibodies.

    Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL.

    Time frame: At Year 10 pre booster vaccination (PRE) and at 1 month post Year 10 booster vaccination (POST)

  13. Number of Booster Responders to Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antigens.

    A booster responder to PT/PRN antigens was defined as either a vaccinated subject seronegative at analysis baseline (Year 10) with anti-PT/anti-PRN antibody concentration greater than or equal to (≥) 5 EL.U/mL at one month post Year 10 booster vaccination, or as a vaccinated subject seropositive at analysis baseline (Year 10) and with anti-PT/anti-PRN antibody concentration with at least a 2-fold increase at one month post Year 10 booster vaccination. A seronegative/seropositive subject was defined as a vaccinated subject with anti-PT/anti-PRN antibody concentration ≥/\< 5 EL.U/mL.

    Time frame: At 1 month post Year 10 booster vaccination

Secondary outcomes

  1. Number of Subjects With Any Solicited Local Symptoms.

    Assessed solicited local symptoms were pain, redness and swelling at the injection site. Any = incidence of a particular symptom regardless of intensity grade.

    Time frame: During the 4-day (Days 0-3) follow-up period after booster vaccination

  2. Number of Subjects With Any Solicited General Symptoms.

    Assessed solicited general symptoms were fatigue, gastrointestinal, headache and fever \[defined as axillary temperature ≥ 37.5 degrees Celsius (°C)\]. Any = incidence of a particular symptom regardless of intensity grade and relationship to vaccination.

    Time frame: During the 4-day (Days 0-3) follow-up period after booster vaccination

  3. Number of Subjects With Any Unsolicited Adverse Events (AEs).

    An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any unsolicited AE = any unsolicited AE regardless of intensity or relationship to vaccination.

    Time frame: During the 31-day (Days 0-30) follow-up period after booster vaccination

  4. Number of Subjects With Any Serious Adverse Events (SAEs).

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject..

    Time frame: At Year 8.5

  5. Number of Subjects With Any Serious Adverse Events (SAEs).

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.

    Time frame: From Year 8.5 up to study end (one month post Year 10 booster vaccination)

07

Results

Posted Oct 8, 2013

Participant flow

Subjects consisted of those previously vaccinated \& boosted in GSK263855/029 study and contacted for participation in this booster (BST) study. Duration of this study was about 19 months, from Year 8.5 (8.5 years post BST in GSK263855/029 study) to one month post BST in this study (Year 10 \[10 years post BST in GSK263855/029 study\] + one month).

At Year 8.5
Participant flow — At Year 8.5
MilestoneBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Started546066
Completed546066
Not completed000
At Year 10
Participant flow — At Year 10
MilestoneBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Started556062
Completed555962
Not completed010
Withdrew: Lost to follow-up010

Outcome measures

PrimaryNumber of Seroprotected Subjects Against Diphtheria and Tetanus

A subject seroprotected against diphtheria/tetanus was defined as a vaccinated subject who had an anti-diphtheria (anti-D)/anti-tetanus (anti-T) antibody concentration greater than or above (≥) 0.1 international units per milliliter (IU/mL).

Time frame:
At Year 8.5
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Diphtheria and Tetanus
ParticipantsBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Anti-D535965
Anti-T545965
PrimaryConcentrations for Anti-D and Anti-T Antibodies.

Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL for all antibodies assessed.

Time frame:
At Year 8.5
Reported as:
Geometric mean · IU/mL
Concentrations for Anti-D and Anti-T Antibodies.
IU/mLBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Anti-D0.912 (0.728 to 1.141)1.205 (0.984 to 1.474)0.872 (0.711 to 1.068)
Anti-T1.889 (1.585 to 2.251)1.991 (1.674 to 2.368)1.846 (1.604 to 2.123)
PrimaryNumber of Seroprotected Subjects Against Diphtheria and Tetanus.

A subject seroprotected against diphtheria/tetanus was defined as a vaccinated subject who had an anti-D/anti-T antibody concentration greater than or above (≥) 0.1 international units per milliliter (IU/mL).

Time frame:
At Year 10
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Diphtheria and Tetanus.
ParticipantsBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Anti-D536061
Anti-T546061
PrimaryConcentrations for Anti-D and Anti-T Antibodies.

Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL.

Time frame:
At Year 10
Reported as:
Geometric mean · IU/mL
Concentrations for Anti-D and Anti-T Antibodies.
IU/mLBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Anti-D0.767 (0.600 to 0.982)1.099 (0.882 to 1.370)0.681 (0.550 to 0.844)
Anti-T2.008 (1.650 to 2.444)2.009 (1.701 to 2.372)1.760 (1.518 to 2.041)
PrimaryNumber of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Haemagglutinin (Anti-FHA) Antibodies.

A seropositive subject for anti-PT/anti-PRN/anti-FHA antibodies was defined as a vaccinated subject who had anti-PT/anti-PRN/anti-FHA antibody concentrations greater than or equal to (≥) 5 Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

Time frame:
At Year 8.5
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-pertussis Toxoid (Anti-PT), Anti-pertactin (Anti-PRN) and Anti-filamentous Haemagglutinin (Anti-FHA) Antibodies.
ParticipantsBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Anti-PT [N=54;59;65]424860
Anti-FHA [N=54;59;62]545962
Anti-PRN [N=54;59;65]545965
PrimaryConcentrations for Anti-PT, Anti-PRN and Anti-FHA Antibodies.

Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL for all antibodies assessed.

Time frame:
At Year 8.5
Reported as:
Geometric mean · EL.U/mL
Concentrations for Anti-PT, Anti-PRN and Anti-FHA Antibodies.
EL.U/mLBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Anti-PT [N=54;59;65]10.933 (7.979 to 14.980)13.372 (10.139 to 17.634)18.034 (13.812 to 23.545)
Anti-FHA [N=54;59;62]72.653 (57.904 to 91.158)96.144 (75.613 to 122.250)102.604 (85.687 to 122.861)
Anti-PRN [N=54;59;65]161.349 (121.750 to 213.827)179.027 (136.303 to 235.144)134.616 (106.266 to 170.528)
PrimaryNumber of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN Antibodies.

A seropositive subject for anti-PT/anti-FHA/anti-PRN antibodies was defined as a vaccinated subject who had anti-PT/anti-FHA/anti-PRN antibody concentrations greater than or equal to (≥) 5 Enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

Time frame:
At Year 10
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN Antibodies.
ParticipantsBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Anti-PT [N=52;59;59]444951
Anti-PRN [N=54;60;60]546060
Anti-FHA [N=54;60;60]546060
PrimaryConcentrations for Anti-PT, Anti-FHA and Anti-PRN Antibodies.

Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL.

Time frame:
At Year 10
Reported as:
Geometric mean · EL.U/mL
Concentrations for Anti-PT, Anti-FHA and Anti-PRN Antibodies.
EL.U/mLBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Anti-PT [N=52;59;59]11.627 (8.863 to 15.252)13.987 (10.874 to 17.991)15.728 (11.760 to 21.034)
Anti-PRN [N=54;60;60]131.814 (98.531 to 176.340)158.239 (120.864 to 207.171)115.209 (91.288 to 145.398)
Anti-FHA [N=54;60;60]75.574 (61.018 to 93.603)98.182 (77.166 to 124.921)98.441 (82.710 to 117.165)
PrimaryNumber of Seroprotected Subjects Against Diphtheria and Tetanus

A subject seroprotected against diphtheria/tetanus was defined as a vaccinated subject who had an anti-D/anti-T antibody concentration greater than or above (≥) 0.1 international units per milliliter (IU/mL).

Time frame:
At Year 10 pre booster vaccination (PRE) and at 1 month post Year 10 booster vaccination (POST)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Diphtheria and Tetanus
ParticipantsBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Anti-D, PRE535960
Anti-D, POST545960
Anti-T, PRE545960
Anti-T, POST545960
PrimaryConcentrations for Anti-D and Anti-T Antibodies.

Concentrations were expressed as geometric mean concentrations (GMCs). The seroprotection cut-off of the assay was 0.1 IU/mL for all antibodies assessed.

Time frame:
At Year 10 pre booster vaccination (PRE) and at 1 month post Year 10 booster vaccination (POST)
Reported as:
Geometric mean · IU/mL
Concentrations for Anti-D and Anti-T Antibodies.
IU/mLBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Anti-D, PRE0.767 (0.600 to 0.982)1.094 (0.874 to 1.368)0.686 (0.552 to 0.853)
Anti-D, POST4.251 (3.646 to 4.957)5.226 (4.353 to 6.275)4.150 (3.543 to 4.862)
Anti-T, PRE2.008 (1.650 to 2.444)1.987 (1.680 to 2.350)1.752 (1.508 to 2.037)
Anti-T, POST7.581 (6.523 to 8.809)8.456 (7.294 to 9.802)8.792 (7.582 to 10.195)
PrimaryNumber of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN Antibodies.

A seropositive subject for anti-PT/anti-PRN/anti-FHA antibodies was defined as a vaccinated subject who had anti-PT/anti-PRN/anti-FHA antibody concentrations greater than or equal to (≥) 5 ELISA units per milliliter (EL.U/mL).

Time frame:
At Year 10 pre booster vaccination (PRE) and at 1 month post Year 10 booster vaccination (POST)
Reported as:
Count of participants · Participants
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN Antibodies.
ParticipantsBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Anti-PT, PRE [N=52;58;58]444850
Anti-PT, POST [N=54;59;60]545960
Anti-PRN, PRE [N=54;59;59]545959
Anti-PRN, POST [N=53;59;60]535960
Anti-FHA, PRE [N=54;59;59]545959
Anti-FHA, POST [N=53;59;60]535960
PrimaryConcentrations for Anti-PT, Anti-FHA and Anti-PRN Antibodies.

Concentrations were expressed as geometric mean concentrations (GMCs). The seropositivity cut-off of the assay was 5 EL.U/mL.

Time frame:
At Year 10 pre booster vaccination (PRE) and at 1 month post Year 10 booster vaccination (POST)
Reported as:
Geometric mean · EL.U/mL
Concentrations for Anti-PT, Anti-FHA and Anti-PRN Antibodies.
EL.U/mLBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Anti-PT, PRE [N=52;58;58]11.627 (8.863 to 15.252)14.193 (11.003 to 18.306)15.650 (11.643 to 21.035)
Anti-PT, POST [N=54;59;60]82.478 (66.951 to 101.606)108.094 (87.703 to 133.227)123.964 (103.458 to 148.533)
Anti-PRN, PRE [N=54;59;59]131.814 (98.531 to 176.340)161.903 (123.574 to 212.120)114.226 (90.201 to 144.652)
Anti-PRN, POST [N=53;59;60]445.751 (372.770 to 533.020)448.475 (383.748 to 524.120)448.839 (379.488 to 530.863)
Anti-FHA, PRE [N=54;59;59]75.574 (61.018 to 93.603)96.098 (75.507 to 122.305)97.698 (81.891 to 116.555)
Anti-FHA, POST [N=53;59;60]503.532 (426.524 to 594.444)592.177 (516.831 to 678.507)558.648 (489.266 to 637.869)
PrimaryNumber of Booster Responders to Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antigens.

A booster responder to PT/PRN antigens was defined as either a vaccinated subject seronegative at analysis baseline (Year 10) with anti-PT/anti-PRN antibody concentration greater than or equal to (≥) 5 EL.U/mL at one month post Year 10 booster vaccination, or as a vaccinated subject seropositive at analysis baseline (Year 10) and with anti-PT/anti-PRN antibody concentration with at least a 2-fold increase at one month post Year 10 booster vaccination. A seronegative/seropositive subject was defined as a vaccinated subject with anti-PT/anti-PRN antibody concentration ≥/\< 5 EL.U/mL.

Time frame:
At 1 month post Year 10 booster vaccination
Reported as:
Count of participants · Participants
Number of Booster Responders to Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN) Antigens.
ParticipantsBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Booster responses to anti-PT [N=44;51;51]445148
Booster responses to anti-PRN [N=45;52;52]232935
Booster responses to anti-FHA [N=46;52;50]434748
SecondaryNumber of Subjects With Any Solicited Local Symptoms.

Assessed solicited local symptoms were pain, redness and swelling at the injection site. Any = incidence of a particular symptom regardless of intensity grade.

Time frame:
During the 4-day (Days 0-3) follow-up period after booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any Solicited Local Symptoms.
ParticipantsBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Any Pain505554
Any Redness232321
Any Swelling212019
SecondaryNumber of Subjects With Any Solicited General Symptoms.

Assessed solicited general symptoms were fatigue, gastrointestinal, headache and fever \[defined as axillary temperature ≥ 37.5 degrees Celsius (°C)\]. Any = incidence of a particular symptom regardless of intensity grade and relationship to vaccination.

Time frame:
During the 4-day (Days 0-3) follow-up period after booster vaccination
Reported as:
Number · subjects
Number of Subjects With Any Solicited General Symptoms.
subjectsBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Any Fatigue172022
Any Gastrointestinal Symptoms10913
Any Headache131913
Any Fever111
SecondaryNumber of Subjects With Any Unsolicited Adverse Events (AEs).

An unsolicited AE is any AE (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any unsolicited AE = any unsolicited AE regardless of intensity or relationship to vaccination.

Time frame:
During the 31-day (Days 0-30) follow-up period after booster vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any Unsolicited Adverse Events (AEs).
ParticipantsBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Number of Subjects With Any Unsolicited Adverse Events (AEs).221621
SecondaryNumber of Subjects With Any Serious Adverse Events (SAEs).

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject..

Time frame:
At Year 8.5
Reported as:
Count of participants · Participants
Number of Subjects With Any Serious Adverse Events (SAEs).
ParticipantsBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Number of Subjects With Any Serious Adverse Events (SAEs).000
SecondaryNumber of Subjects With Any Serious Adverse Events (SAEs).

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.

Time frame:
From Year 8.5 up to study end (one month post Year 10 booster vaccination)
Reported as:
Count of participants · Participants
Number of Subjects With Any Serious Adverse Events (SAEs).
ParticipantsBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
Number of Subjects With Any Serious Adverse Events (SAEs).000

Adverse events

Collected over Serious adverse events (SAEs): Entire study period (From Year 8.5 to one month post Year 10) ; Unsolicited adverse events (AEs): During the 31 days (Day 0 - Day 30) post Year 10 booster vaccination; Solicited symptoms: During the 4 days (Day 0 - Day 3) post Year 10 booster vaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Boostrix-US Group—0/55 (0%)53/55 (96.4%)
Boostrix-INV Group—0/60 (0%)58/60 (96.7%)
Boostrix-REF Group—0/66 (0%)58/62 (93.5%)
Most frequent other events
Most frequent other events
EventBoostrix-US GroupBoostrix-INV GroupBoostrix-REF Group
PainGeneral disorders50/5555/5954/62
RednessGeneral disorders23/5523/5921/62
SwellingGeneral disorders21/5520/5919/62
FatigueGeneral disorders17/5420/5922/62
HeadacheGeneral disorders13/5419/5913/62
Gastrointestinal symptomsGeneral disorders10/549/5913/62
NasopharyngitisInfections and infestations6/551/604/62
HeadacheNervous system disorders5/551/603/62

Baseline characteristics

At Year 8.5, a total of 180 subjects (out of the 478 planned) were enrolled: 54, 60 and 66 subjects in the Boostrix-REF, Boostrix-US, and Boostrix-INV groups, respectively. At Year 10, a total of 177 subjects (out of the 180 planned) were enrolled: 55, 60 and 62 in the Boostrix-REF, Boostrix-US, and Boostrix-INV groups, respectively.

Age, Continuous
Age, Continuous(Years)Boostrix-US GroupBoostrix-INV GroupBoostrix-REF GroupTotal
Mean22.4 ± 1.4622.3 ± 1.2022.3 ± 1.1722.3 ± 1.18
Age, Continuous
Age, Continuous(Years)Boostrix-US GroupBoostrix-INV GroupBoostrix-REF GroupTotal
Mean23.5 ± 1.4423.4 ± 1.2123.3 ± 1.1723.4 ± 1.19
Sex: Female, Male
Sex: Female, Male(Participants)Boostrix-US GroupBoostrix-INV GroupBoostrix-REF GroupTotal
Female293339101
Male25272779
Sex: Female, Male
Sex: Female, Male(Participants)Boostrix-US GroupBoostrix-INV GroupBoostrix-REF GroupTotal
Female29313696
Male26292681
08

Study locations

3 sites
  • GSK Investigational Site
    Bruxelles, 1200, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Wilrijk, 2610, Belgium
09

References and documents

Publications

  • Vandermeulen C, Theeten H, Rathi N, Kuriyakose S, Han HH, Sokal E, Hoppenbrouwers K, Van Damme P. Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium. Vaccine. 2015 Jun 12;33(26):3026-34. doi: 10.1016/j.vaccine.2014.10.049. Epub 2015 Jan 19. PubMed 25613716 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of May 2012 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2010
First posted
Jun 22, 2010
Start
Jun 15, 2010
Primary completionActual
May 8, 2012
CompletionActual
May 8, 2012
Results first posted
Oct 8, 2013
Last update
Aug 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01147900
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 22, 2010
Start date
Jun 15, 2010
Primary completion
May 8, 2012
Completion
May 8, 2012
Results posted
Oct 8, 2013
Last update
Aug 20, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Boostrix

Start the discussion